Supplemental Figure 1  Expression of UHRF1 detected by TaqMan qRT-PCR and many characteristics of patients were compared by Mann-Whitney’s U-test.

A. Expression levels of UHRF1 in female patients (n=29) and male patients (n=75). Gender was not associated with expression levels of UHRF1 ($p=0.2162$).

B. Expression levels of UHRF1 in patients with tumours four and less (n=53) and more than four (n=9) were not different ($p=0.2896$).

C. Expression levels of UHRF1 in patients with $\leq 5$ cm tumours (n=38) and with >5 cm tumours (n=20) were not different ($p=0.4567$).

D. Expression levels of UHRF1 in patients with papillary type tumours (n=32) and with solid or solid/papillary tumours (n=28) were not different ($p=0.6092$).

E. Expression levels of UHRF1 in patients who did not have a recurrence (n=19) and have a recurrence (n=46) were not different ($p=0.6239$).

F. Expression levels of UHRF1 in patients who survived 5 years after surgery (n=45) and died within 5 years (n=48) were not different ($p=0.4151$).

G. Expression levels of UHRF1 in non-smoker patients (n=22) and smoker patients including 4 ex-smokers (n=40) was not different ($p=0.0750$). $\beta_2$-microgloblin was used for normalization.
Supplemental Figure 2 Expression of p53 and UHRF1 in bladder cancers detected by immunohistochemistry.
Supplemental Figure 3  Relative expression levels of *UHRF1* in peripheral blood mononuclear cells (PBMCs) were examined by TaqMan qRT-PCR. Almost no expression of *UHRF1* was detected in PBMCs.